Schizophrenic Patients on Long-term Oral/Topical Antipsychotic Treatment Without a Trial of Atypical Long-acting Injectable Therapy: A Tenncare Initiative
This E-newsletter will provide an overview of the program, including details regarding the benefits of LAI atypical antipsychotics and other available agents, a brief review of schizophrenia and potential clinical steps. Additional information regarding the retrospective drug utilization review process and the rationale for brand drug preference will also be highlighted.
Category
  • Behavioral health
Format
  • E-monographs
Credits
  • 0.50 ACPE - Pharmacists
  • 0.50 ACPE - Pharmacy Technicians
  • 0.50 AMA - Physicians
  • 0.50 ANCC - Nurses
  • 0.50 Attendance - General Attendance
Cost $0.00